Wegovy Maker Novo Nordisk Sales Rise 18% In Second Quarter

Reuters08-06

Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a major profit warning and new CEO announcement last week wiped some $95 billion of value from the company's stock.

Novo Nordisk shares jumped 4% in overnight trading.

The Danish drugmaker, which boomed to become Europe's most valuable firm worth some $650 billion last year on the back of sales of its blockbuster weight-loss drug, is facing a pivotal moment as it battles rising competition that is denting sales.

The company repeated its full-year guidance, days after slashing its 2025 sales outlook and replacing CEO Lars Fruergaard Jorgensen with veteran insider Maziar Mike Doustdar. Its market cap has fallen since peak to some $212 billion.

"We are taking measures to sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth," outgoing CEO Jorgensen said in a statement.

Doustdar will take the helm on Thursday, with the firm facing tough questions from investors about how it can stay competitive in the booming weight-loss drug market against U.S. rival Eli Lilly LLY.N and a wave of compounded copycat versions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

12

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2557886340?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 13:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557886340","market":"fut","top_or_hot":-1,"title":"Wegovy Maker Novo Nordisk Sales Rise 18% In Second Quarter","media":"Reuters","content":"<html><head></head><body><p>Wegovy-maker <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a major profit warning and new CEO announcement last week wiped some $95 billion of value from the company&#39;s stock.</p><p>Novo Nordisk shares jumped 4% in overnight trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/8f5400004a01a3659a9b5f82461bf27d\" tg-width=\"844\" tg-height=\"822\"/></p><p>The Danish drugmaker, which boomed to become Europe&#39;s most valuable firm worth some $650 billion last year on the back of sales of its blockbuster weight-loss drug, is facing a pivotal moment as it battles rising competition that is denting sales.</p><p>The company repeated its full-year guidance, days after slashing its 2025 sales outlook and replacing CEO Lars Fruergaard Jorgensen with veteran insider Maziar Mike Doustdar. Its market cap has fallen since peak to some $212 billion.</p><p>&#34;We are taking measures to sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth,&#34; outgoing CEO Jorgensen said in a statement.</p><p>Doustdar will take the helm on Thursday, with the firm facing tough questions from investors about how it can stay competitive in the booming weight-loss drug market against U.S. rival <a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a> LLY.N and a wave of compounded copycat versions.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wegovy Maker Novo Nordisk Sales Rise 18% In Second Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWegovy Maker Novo Nordisk Sales Rise 18% In Second Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-06 13:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Wegovy-maker <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a major profit warning and new CEO announcement last week wiped some $95 billion of value from the company&#39;s stock.</p><p>Novo Nordisk shares jumped 4% in overnight trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/8f5400004a01a3659a9b5f82461bf27d\" tg-width=\"844\" tg-height=\"822\"/></p><p>The Danish drugmaker, which boomed to become Europe&#39;s most valuable firm worth some $650 billion last year on the back of sales of its blockbuster weight-loss drug, is facing a pivotal moment as it battles rising competition that is denting sales.</p><p>The company repeated its full-year guidance, days after slashing its 2025 sales outlook and replacing CEO Lars Fruergaard Jorgensen with veteran insider Maziar Mike Doustdar. Its market cap has fallen since peak to some $212 billion.</p><p>&#34;We are taking measures to sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth,&#34; outgoing CEO Jorgensen said in a statement.</p><p>Doustdar will take the helm on Thursday, with the firm facing tough questions from investors about how it can stay competitive in the booming weight-loss drug market against U.S. rival <a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a> LLY.N and a wave of compounded copycat versions.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nL8N3TW0GF:1","article_id":"2557886340","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557886340","pubTimestamp":1754458600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"COPENHAGEN, Aug 6  - Wegovy-maker Novo Nordisk NOVOb.CO reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a major profit warning and new CEO announcement last week wiped some $95 billion of value from the company's stock.  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4599":"减肥药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4585":"ETF&股票定投概念","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK7104":"黄金","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","BK4007":"制药","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0385154629.USD":"贝莱德营养科学基金A2","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","BK4588":"碎股","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","NVO":"诺和诺德"},"translate_title":"Wegovy制造商诺和诺德第二季度销售额增长18%","themeId":"70f4f81b14d99bf2a8bc071eb02154af","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a major profit warning and new CEO announcement last week wiped some $95 billion of value from the company's stock.Novo Nordisk shares jumped 4% in overnight trading.The Danish drugmaker, which boomed to become Europe's most valuable firm worth some $650 billion last year on the back of sales of its blockbuster weight-loss drug, is facing a pivotal moment as it battles rising competition that is denting sales.The company repeated its full-year guidance, days after slashing its 2025 sales outlook and replacing CEO Lars Fruergaard Jorgensen with veteran insider Maziar Mike Doustdar. Its market cap has fallen since peak to some $212 billion.\"We are taking measures to sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth,\" outgoing CEO Jorgensen said in a statement.Doustdar will take the helm on Thursday, with the firm facing tough questions from investors about how it can stay competitive in the booming weight-loss drug market against U.S. rival Eli Lilly LLY.N and a wave of compounded copycat versions.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":12,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":true,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557886340","isCrawlerRequest":true}